A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Duke University
National Institutes of Health Clinical Center (CC)
University of California, San Diego
University of Copenhagen
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Charles Drew University of Medicine and Science
Health Clinics Limited
BioXcel Therapeutics Inc
NKGen Biotech, Inc.
St. Joseph Hospital of Orange
Cedars-Sinai Medical Center
University of Ottawa
Indiana University
University of California, San Diego
Piedmont Cancer Institute
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center
The University of Texas Medical Branch, Galveston
Galectin Therapeutics Inc.
Western Regional Medical Center
Johns Hopkins University
Merrimack Pharmaceuticals
University of Pennsylvania
M.D. Anderson Cancer Center
Weill Medical College of Cornell University
New Hope Medical Center
Karolinska Institutet